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Summary The 15-year findings are presented of a double-blind, randomised study planned in 1964 in which
cytotoxic chemotherapy with either busulphan or cyclophosphamide prescribed to be given daily for 2 years as
an adjuvant to surgery was compared with placebo in the treatment of 726 patients with carcinoma of the
bronchus. The two cytotoxic agents administered in this way did not influence survival. At 15y, 8% of the
243 patients allocated busulphan, 9% of the 234 cyclophosphamide, and 10% of the 249 placebo were alive,
these being 10% of the patients who had had epidermoid cancers, 12% large-cell, 5% small-cell, 5%
adenocarcinomas, and 8% other histological types. The study provides data on long-term results in a large
group of patients who were, in effect, treated by surgery alone. Survival was significantly shorter in patients
with histological involvement of the resected intrathoracic nodes (log-rank test P<<0.001). A finding of
particular interest is that the histological type of the tumour did not influence survival in the 390 patients
whose nodes were not involved, although, as expected, it did in the 336 whose nodes were involved, the 226
with epidermoid cancers surviving longer than the 57 with small cell carcinoma, the 31 with adenocarcinoma
and all 110 with non-epidermoid carcinomas (P<<0.001 in each comparison).
The results at 5 years (Stott et al., 1976) of a
Medical Research Council Working Party double-
blind study, planned in 1964, to find out whether 2
years ofdaily chemotherapy with busulphan orcyclo-
phosphamide, compared with placebo, following
surgical removal of bronchial carcinoma would
suppress metastases and prolong survival, showed
no benefit from either of these cytotoxic agents in
the dosage schedules studied. Moreover, there was
a high incidence of haematological toxicity to
busulphan. All the survivors have now been studied
for 15 years and the findings are presented in this
report.
Plan and conduct of the study
The plan and conduct of the study were described
in detail previously (Medical Research Council,
1971). In summary, after resection of all intra-
thoracic bronchial tumour, the patients were
allocated at random to receive tablets of busulphan
(B series), cyclophosphamide (C series), or
indistinguishable placebos (P series) daily for 2
years. For the first 10 days following operation, all
patients received 8 tablets in a single daily dose (B
series 4 mg, C series 200mg). Thereafter they
received 6 tablets daily (B series 3 mg, C series
150mg). However, after about the first year of
intake to the study, these maintenance dosages were
reduced from 6 to 3 tablets (B series 1.5 mg, C
series 75mg), because of an unexpectedly high
incidence of toxicity. The 3 series were very similar
with respect to sex, age, type of operation,
bronchial site of tumour, histological type of
tumour, and whether or not the resected lymph-
nodes were histologically involved.
Each patient was reported on monthly during the
first 3 years, 3-monthly up to 5 years, and annually
thereafter. Total leucocyte and platelet counts and
haemoglobin concentrations were measured every
month during the first 2 years, and thereafter when
requested by the clinician. The maintenance dose of
tablets was controlled by the clinician from the
results of the blood investigations and the dose was
reduced ifhaematological toxicity was suspected.
The study was conducted double-blind. The
certified cause of death was obtained from the local
centre and was verified from the death entries at
the OPCS for all but 2 of the deaths.
It is important to note that as the study was
planned in 1964, some of the peri-operative staging
procedures which would now be considered
desirable were not required as a routine and when
done were not necessarily reported. In particular,
the following were not specifically requested as part
of the protocol: recording recent weight loss,
mediastinoscopy, isotope scans, liver function tests,
marrow aspiration or biopsy, routine dissection of
the mediastinal nodes at operation, or reporting the
size of the tumour in the resected specimen.
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Results
The only important difference between patients
prescribed the two maintenance dosage schedules
was the incidence of toxicity. The amalgamated
results are therefore presented.
Survival up to 15 years
The survival curves (Figure 1) show no statistically
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significant difference between the 3 series (log-rank
tests). Even within the group of 83 patients with
small cell carcinoma, treatment series had no effect
on survival. The survivors at 5, 10 and 15 y are
shown in Table I according to the series and the
histological type of carcinoma. At 15y, 8% of the
B, 9% of the C and 10% of the P patients were
alive, these being 10% of the patients with
epidermoid cancers, 12% of those with large cell
cancers, 5% of those with small cell cancers, 5% of
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Figure 1 Survival from date of allocation.
Table I Survivors at 5, 10, and 15 years according to series and histological
type of tumour
Survivors at
Total 5 years 10 years 15 years
patients n. (0) n. (%) n. (%)
Series:
Busulphan 243 69 (28) 34 (14) 20 (8)
Cyclophosphamide 234 63 (27) 33 (14) 21 (9)
Placebo 249 85 (34) 59 (24) 25 (10)
Histological type:
- epidermoid 518 176 (34) 99 (19) 52 (10)
- large cell 51 12 (24) 10 (20) 6 (12)
- small cell 83 12 (14) 7 (8) 4 (5)
- adenocarcinoma 62 11 (18) 5 (8) 3 (5)
- other 12 6 (50)' 5 (42)' 1 (8)'
Total patients 726 217 (30) 126 (17) 66 (9)
aPercentages based on fewer than 25 observations.
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those with adenocarcinomas, and 8% of those with
other histological types.
The mean age of the 66 survivors at 15 y was 71 y
(range 49-85). Their general condition was reported
as 'good' for 49 (74%), 'fair' for 15 (23%), and
'poor' for only 2 (3%); 38 (58%) were fully active,
a further 25 (38%) were out and about but with
restricted activity, and only 3 (5%) were confined
to home or hospital or were bedridden.
Cause ofdeath
The proportions of patients certified as having died
from bronchial carcinoma were similar in the 3
series. By 5y, 144 (59%) of the B, 142 (61%) of the
C, and 141 (57%) of the P patients had been so
certified. By 10y, these figures had risen to 167
(69%), 160 (68%), and 156 (63%), and by 15y to
171 (70%), 167 (71%), and 168 (67%), respectively.
The proportion of total deaths due to bronchial
carcinoma was 427 (84%) of the 509 during the
first 5 years, compared with 56 (62%) of the 91
during years 6 to 10, and 23 (38%) of the 60 during
years 11 to 15, there being no statistically
significant differences between the 3 series.
Evidence ofmetastases
Metastases were reported to have been definitely
present at some time during the 15 y (Table II) in
131 (54%) of the 243 B, 111 (47%) of the 234 C,
and 132 (53%) of the 249 P patients, and had been
suspected in a further 25 (10%), 29 (12%), and 28
(11%) respectively. Metastases appeared after
similar periods in the 3 series, most of them during
the first 5 y, namely in 340 (91%) of the 374
patients with definite, and in 77 (94%) of the 82
with suspected metastases.
Of the 374 patients (Table III) with definite
metastases reported, 352 (94%) died from
carcinoma of the bronchus, 18 (5%) from other
causes, and the remaining 4 (1%) were still alive at
Table II Cumulative totals of patients who had had definite and suspected
metastases reported by 5, 10, and 15 years
Patients with metastases by:
Total 5 years 10 years 15 years
Series patients Metastases n. (%) n. (%) n. (%)
Busulphan 243 definite 118 (49) 129 (53) 131 (54)
suspected 23 (9) 24 (10) 25 (10)
none 102 (42) 90 (37) 87 (36)
Cyclophosphamide 234 definite 102 (44) 109 (47) 111 (47)
suspected 29 (12) 29 (12) 29 (12)
none 103 (44) 96 (41) 94 (40)
Placebo 249 definite 120 (48) 125 (50) 132 (53)
suspected 25 (10) 26 (10) 28 (11)
none 104 (42) 98 (39) 89 (36)
All series 726 definite 340 (47) 363 (50) 374 (52)
suspected 77 (11) 79 (11) 82 (11)
none 309 (43) 284 (39) 270 (37)
Table III The relationship between the presence of
outcome at 15 years
metastases and the
Evidence ofmetastases by 15 years
Definite Suspected None Total
Outcome at 15 years n. (%) n. (%) n. (%) n. (%)
Died from carcinoma
of the bronchus 352 (94) 77 (94) 77 (29) 506 (70)
Died from other causes 18 (5) 5 (6) 131 (49) 154 (21)
Alive 4 (1) 0 (0) 62 (23) 66 (9)
Total 374 (100) 82 (100) 270 (100) 726 (100)870 D.J. GIRLING et al.
Table IV The relationship between pretreatment factors and deaths certified as due
to bronchial carcinoma
Patients Diedfrom
assessed bronchial carcinoma
Pretreatmentfactor A No. % of A
Sex:
- male
- female
Age (years):
- less than 55
-55 to 64
- 65 or more
Histological type:
- epidermoid
- large cell
- small cell
- adenocarcinoma
- other
Operation:
- segmental resection
- lobectomy
- pneumonectomy
Bronchial site:
Right
- main
- upper lobe
- middle lobe
- lower lobe
Left
- main
- upper lobe
- lower lobe
Resected intrathoracic nodes histologically:
- not involved
- involved
bronchopulmonary only
hilar, but not mediastinal
mediastinal
Total
Total patients
670 461 (69)
56 45 (80)
175
392
159
518
51
83
62
12
12
339
375
18
151
28
139
35
229
126
390
108
149
79
336
726
120
278
108
352
36
62
49
7
9
223
274
8
107
19
87
28
163
94
244
80
118
64
262
506
(69)
(71)
(68)
(68)
(71)
(75)
(79)
(58)8
(75)8
(66)
(73)
(44)a
(71)
(68)
(63)
(80)
(71)
(75)
(63)
(74)
(79)
(81)
(78)
70
aPercentages based on fewer than 2. observations.
A regression analysis showed that the factor with the greatest influence on survival
was whether the resected intrathoracic nodes were histologically involved. Histological
type was also important, but only when the nodes were involved.
15 years. The corresponding percentages for
patients with suspected metastases were very
similar. In comparison, of the 270 patients with no
metastases reported, 77 (29%) died from carcinoma
of the bronchus, 131 (49%) from other causes, and
62 (23%) were still alive at 15 years.
Influence ofpretreatmentfactors on mortalityfrom
bronchial carcinoma
The main pretreatment factors related to deaths
certified as due to bronchial carcinoma are shown
in Table IV. A Cox (1972) model regression
analysis using the same factors as in Table IV in
addition to treatment series was done to determine
which factors had the greatest influence on time of
death from bronchial carcinoma. This analysis
indicated that the most important factor was
whether the patient had histological involvement of
the resected intrathoracic nodes. This was
confirmed by log-rank test (P<0.00001). WithinCHEMOTHERAPY FOR LUNG CANCER 871
the group of 336 patients whose nodes were
involved, histological type was important, the 226
patients with epidermoid carcinoma surviving
significantly longer than the 57 with small cell
carcinomas (log-rank test P<0.00001), the 31 with
adenocarcinoma (P=0.00002), and all 110 with
non-epidermoid carcinomas (P<0.00001). The only
other factor to have a significant effect was the site
of the involved nodes, the patients with involve-
ment of (a) bronchopulmonary nodes only surviving
for longer than those with (b) hilar, but not
mediastinal, node involvement and those with
(c) mediastinal node involvement (P<0.001 for the
trend).
In contrast, within the group of 390 patients
without node involvement, there were no significant
pretreatment prognostic factors, not even
histological type.
The figures for the population as a whole (Table
IV) appear to suggest that segmental resection was
as effective as lobectomy. However, such a
conclusion would be unwarranted, first because of
the small number of patients who had a segmental
resection (only 12), and secondly because none of
the 12 had intrathoracic nodes involved. Indeed,
among the 390 patients without node involvement,
9 (75%) of the 12 who had a segmental resection
died of bronchial carcinoma compared with 142
(62%) of the 229 who had a lobectomy, and 93
(62%) of the 149 who had a pneumonectomy.
As would be expected, when deaths from all
causes were considered in the regression analysis,
age also had an important influence on mortality.
Additional treatment after 5 years
During years 6 to 10, 14 patients (6B, 5C, 3 P)
received treatment for extension or recurrence of
their bronchial carcinoma, 3 (1 B, 1C, 1 P) chemo-
therapy, 7 (2B, 3C, 2P) radiotherapy, 2 (both B)
chemotherapy and radiotherapy, and 2 (1B, 1C)
surgery. For 13, treatment was for local spread of
the disease, and for the 14th for cerebral
metastases. During years 11 to 15, 7 patients (2B,
2C, 3P) received treatment, all for local extension
of the disease from the primary site; 6 receiving
radiotherapy, and 1 (B) chemotherapy.
Otherprimary neoplasms
During the 15 years, 34 patients (12B, 7C, 15P)
had at least 1 other primary malignant neoplasm in
addition to bronchial carcinoma. In 33 only 1 other
site was involved; 9 (4B, 2C, 3P) had tumours of
the stomach, 4 (1 B, 1 C, 2P) of the bladder, 3 (2B,
1 P) of the skin, 3 (all P) of the rectum, 3 (1 B, 1 C,
1 P) of the colon, 2 (1 C, 1 P) of the prostate, and 1
each of the opposite lung with different histology
(C), the larynx (C), the pancreas (P), the cervix (P)
and the nasopharynx (P), and 4 (all B) had acute
leukaemia. The remaining patient (P) had 2 other
primary neoplasms, namely, of the colon and of the
prostate. The 4 cases of leukaemia have been
reported elsewhere (Stott et al., 1977).
The time interval between admission to the study
and the diagnosis of the second malignancy was 1
to 5y in 10 patients, 6 to 10 in 13 and 11 to 15 in
10 patients. In 1 patient the interval was not
known.
Drug toxicity
Details of drug toxicity have been reported
previously (Stott et al., 1976). There were important
differences between the series with respect to
haematological toxicity, which occurred in 177
(73%) of the B patients compared with 86 (37%)
of the C, 49 (20%) of the P patients having com-
parable episodes (Table V). The commonest mani-
Table V Abnormal haematological results during the first 5 years
Series
Patients with abnormal blood counts B C P
on one or more occasions n. (%) n. (%) n. (%)
All patients with abnormal counts 177 (73) 86 (37) 49 (20)
Thrombocytopenia 172 (71) 49 (21) 36 (14)
(platelet count <100 x1091-1)
Leucopenia 55 (23) 37 (16) 5 (2)
(Total white cell count <3.0 x I0'1 1)
Anaemia 37 (15) 15 (6) 10 (4)
(Hb <9gdl 1)
Pancytopenia 19 (8) 1 (<1) 0 (0)
Total patients 243 (100) 234 (100) 249 (100)872 D.J. GIRLING et al.
festation in all 3 series was thrombocytopenia, and
the difference between the B series and each of the
other 2 series was highly significant (P<0.0001) for
each of the 4 comparisons, namely any haema-
tological toxicity, thrombocytopenia, leucopenia,
and anaemia. Nineteen (8%) of the B patients
developed pancytopenia compared with only 1 of
the C and none of the P patients. All 4 of the B
patients in whom acute leukaemia subsequently
developed were among the 19 who had pancyto-
penia. (Leukaemia has been diagnosed subsequent
to the 15 years of follow-up in 2 further patients in
the B series who will be reported elsewhere.)
Deaths attributable to toxicity
In 4 patients (all B) there was evidence that
chemotherapy had contributed to death during the
first 2 years through marrow depression. A 5th
patient (B) died with pancytopenia in the 3rd year
and 4 patients (all B) died later from acute
leukaemia (Stott et al., 1977).
Discussion
This trial was planned in 1964 to discover, in a
randomised, double-blind, placebo-controlled
comparison, whether 2 years of daily treatment
with either busulphan or cyclophosphamide would
suppress metastases and prolong survival after
intended 'curative' resection of bronchial
carcinoma. At the time, some investigators had
reported favourably on long-term adjuvant
chemotherapy with cyclophosphamide (Denk &
Karrer, 1961; Poulsen, 1962, 1963) and on the
activity of busulphan against inoperable bronchial
carcinoma (Sullivan, 1958). However, the relative
sensitivity of small cell compared with non-small
cell carcinomas to chemotherapy (Green et al.,
1969; Higgins, 1972; Host, 1973; Selawry, 1974),
and the superiority of pulsed chemotherapy with an
interval between each dose (Bergsagel, 1971;
Karrer, 1972) and of treatment with combinations
of drugs (Carbone et al., 1970; Alberto, 1973;
Maurer & Tulloh, 1974; Bunn et al., 1977), were
not then appreciated.
In the event, single-drug postoperative daily
treatment with busulphan or cyclophosphamide in
the dosages studied did not influence survival, 8%
of the 243 patients in the busulphan series, 9% of
the 234 in the cyclophosphamide series, and 10% of
the 249 in the placebo series surviving to 15 years.
Nor did it influence the proportion of patients
certified as having died from bronchial carcinoma
or the frequency and time of detection of definite
or suspected metastases. The study therefore
provides data on the long-term results for 726
patients treated, in effect, by surgery alone, and the
findings on factors which influenced prognosis are
consequently of relevance to the surgical
management ofpatients.
The possible influence of sex, age, type of
operation (segmental resection, lobectomy, or
pneumonectomy), bronchial site of tumour,
histological type of tumour, and whether or not the
resected nodes were histologically involved on the
duration of survival in patients certified as having
died from bronchial carcinoma, was examined in a
Cox model regression analysis. The most important
factor was whether the resected nodes were
histologically involved, and this was confirmed by a
log-rank test (P<0.00001). However, a finding of
particular interest is that the histological type of the
tumour did not influence survival in patients whose
nodes were not involved. This correlates with the
observation by Higgins et al. (1975) that
histological type did not influence survival in
patients who had had an intended 'curative'
resection of an asymptomatic solitary pulmonary
nodule found to be a primary bronchogenic
carcinoma, although they did not report whether
any of these patients had histological involvement
of resected nodes. In the present study, histological
type did influence survival in patients whose nodes
were involved; the 226 patients with epidermoid
carcinoma survived longer than the 57 with small-
cell carcinoma, the 31 with adenocarcinoma, and all
110 with non-epidermoid carcinomas (P<<0.001 for
each comparison). These findings suggest that if
surgical resection is carried out early enough, even
patients with small cell carcinoma may benefit from
surgery. To confirm this a randomised comparison
of surgery and chemotherapy against chemotherapy
alone in the mangement of such patients with
small cell carcinoma would be necessary. However,
the ethics of such a comparison is now open to
question, and a case can be made for offering
surgery to patients with early, stage 1, operable
tumours, whatever the histological type, providing
adequate staging procedures have been carried out.
Nevertheless it must be emphasised that very small
numbers of patients with small cell carcinoma are
likely to have truly stage I disease when diagnosed
(Kron et al., 1982; Spiro & Goldstraw, 1984).
Published information on the possible prognostic
importance of other factors has been conflicting,
largely because no attempt is usually made to
isolate factors which have an independent effect by
means of multiple regression analysis. However,
Clee et al. (1984). in a retrospective study of 337
patients who had a resection for bronchial
carcinoma, examined the effects of 14 preoperative
and 2 operative variables, and found that a
multiple regression analysis identified 4 which had aCHEMOTHERAPY FOR LUNG CANCER 873
statistically significant independent effect, viz. a
history of weight loss, a history of chest pain
developing within 6 months before surgery, the size
of the tumour as assessed on the chest radiographs,
and the histological cell type. These findings,
together with those from the present study, suggest
that many of the other factors which have been
reported to be of prognostic importance, such as
age (Belcher & Anderson, 1965; Higgins et al.,
1969); sex (Watson & Schottenfeld, 1968); type of
operation (Bignall et al., 1967; Pool, 1971) and site
of tumour (Higgins & Beebe, 1967), are unlikely to
have an independent effect, although if all patients,
irrespective of the cause of death, are included, age
does affect prognosis (Higgins et al., 1969, and
present study).
The surgeons, physicians and pathologists who
collaborated in this study are listed in the first report
(Medical Research Council, 1971). Their cooperation is
again acknowledged and appreciated.
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